Decades of basic, translational and clinical research have yielded significant breakthroughs in cancer care – with many cancers now treated as chronic diseases. The AACR’s Cancer Progress Report, to be released Tuesday, outlines how cancer research makes a difference in the lives of patients and in breakthroughs for other diseases and well as the importance of continued investment in cancer research.City of Hope offers the following experts to discuss the report:
Steven T. Rosen, M.D., provost and chief scientific officer. Dr. Rosen sets the scientific direction for City of Hope, is the author of more than 400 original publications, and is the current editor-in-chief of the journal Cancer Treatment & Research. The report underscores the advances in cancer treatment and the importance in continuing to invest in research. “Incredible strides have been made in advancing our understanding, enhancing prevention and improving therapy of cancer. To maintain moment with the ultimate goal of maximizing cure of these devastating diseases the necessary funds must be available.” [email protected]
Stephen J. Forman, M.D., F.A.C.P., Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation. Dr. Forman is an international leader in the field of hematologic malignancy and bone marrow transplantation. He is an expert in immunotherapy, an emerging field of cancer research, specifically in the use of T-cells in immunotherapy. [email protected]
Yuman Fong, M.D., chair, Department of Surgery. A world renowned expert in liver and pancreatic cancer, as well as gene therapy for cancer, Dr. Fong can speak to the issue of access to healthcare and how it impacts cancer survival – especially access to clinical trials and the most advanced medicine. [email protected]
Karen Reckamp, M.D., M.D., co-director, Lung Cancer and Thoracic Oncology Program. Dr. Reckamp’s research interests include targeted chemotherapy to treat lung cancer, which remains the top cause of cancer death and second-leading cause of death in the United States. [email protected]
Joseph Alvarnas, M.D., director, Medical Quality. Dr. Alvarnas focuses on quality and access issues, as well as the importance of access to clinical trials for cancer patients. He is available to give interviews in English or Spanish. [email protected]
Jeffrey Weitzel, M.D., director, Clinical Cancer Genetics. Dr. Weitzel is an expert in genetic testing. His research has found Latinas have a high prevalence of BRCA mutations, which greatly increase breast cancer risk. He was also part of the team that published findings linking mutations in the gene PAL2 to breast cancer risk. [email protected]
For additional assistance or to arrange phone interviews, please contact Nicole White, senior media specialist, at [email protected] or by phone at 626-471-7298.
Nicole
RSS